Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 8—August 2009
Research

Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

Iain StephensonComments to Author , Alan Heath, Diane Major, Robert W. Newman, Katja Hoschler, Wang Junzi, Jacqueline M. Katz, Jerry P. Weir, Maria C. Zambon, and John M. Wood
Author affiliations: University of Leicester, Leicester, UK (I. Stephenson); National Institute for Biological Standards and Controls, Potters Bar, UK (A. Heath, D. Major, R.W. Newman, J.M. Wood); Health Protection Agency, Colindale, UK (K. Hoschler, M.C. Zambon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Katz); Food and Drug Administration, Rockville, Maryland, USA (J.P. Weir); National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China (W. Junzhi)

Main Article

Table 3

Interlaboratory geometric coefficients of variation of absolute titers and titers and relative to candidate antibody standard 07/150 and sheep serum summarized over all serum for each influenza virus tested by hHI and neutralization*

%GCV, virus strain hHI, all serum samples, median (min–max) Neutralization, all serum samples, median (min–max)
%GCV of absolute titer
A/Vietnam/1194/NIBRG-14 clade 1 125 (31–582)† 175 (86–232)†
A/Turkey/23/NIBRG-23 clade 2.2 114 (29–496) 170 (101–283)
A/Anhui/IBCDC-RG5 clade 2.3
 108 (22–487)
 112 (68–147)
%GCV of titers relative to 07/150
A/Vietnam/1194/NIBRG-14 clade 1 61 (34–535) 77 (37–285)
A/Turkey/23/NIBRG-23 clade 2.2 106 (18–487) 144 (33–309)
A/Anhui/IBCDC-RG5 clade 2.3
 105 (0–545)
 196 (41–298)
%GCV of titers relative to serum P
A/Vietnam/1194/NIBRG-14 clade 1 796 (39–1,020) 249 (162–381)
A/Turkey/23/NIBRG-23 clade 2.2 689 (7–953) 237 (90–844)
A/Anhui/IBCDC-RG5 clade 2.3 752 (0–1,005) 195 (66–263)
A/Vietnam/1194/NIBRG-14 clade 1 (excluding laboratory 5) 68 (32–174) 255 (162–396)
A/Turkey/23/NIBRG-23 clade 2.2 (excluding laboratory 5) 70 (7–222) 237 (90–844)
A/Anhui/IBCDC-RG5 clade 2.3 (excluding laboratory 5)
 51 (0–148)
 195 (66–262)
%GCV of titers relative to serum 0
A/Vietnam/1194/NIBRG-14 clade 1 442 (21–725) 78 (41–213)
A/Turkey/23/NIBRG-23 clade 2.2 373 (20–804) 111 (29–204)
A/Anhui/IBCDC-RG5 clade 2.3 306 (0–812) 199 (44–323)
A/Vietnam/1194/NIBRG-14 clade 1 (excluding laboratories 5, 6, 12) 39 (24–91) 82 (34–225)
A/Turkey/23/NIBRG-23 clade 2.2 (excluding laboratories 5, 6, 12) 113 (22–225) 97 (25–186)
A/Anhui/IBCDC-RG5 clade 2.3 100 (0–198) 194 (47–299)

*%GCV, geometric coefficient of variation; hHI, hemagglutination-inhibition assay using horse erythrocytes; neutralization, virus neutralization assay; min–max, minimum–maximum. Boldface indicates homologous clade 1 strain.
†%GCV absolute titer vs. relative 07/150 for NIBRG-14 (*hHI p = 0.001, neutralization p = 0.002; Wilcoxon signed-rank test).

Main Article

Page created: November 01, 2010
Page updated: November 01, 2010
Page reviewed: November 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external